Sodhi Jasleen K, Delarosa Erlie Marie, Halladay Jason S, Driscoll James P, Mulder Teresa, Dansette Patrick M, Khojasteh S Cyrus
Department of Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way (MS 412a), South San Francisco, CA 94080, USA.
Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94143, USA.
Int J Mol Sci. 2017 Jul 20;18(7):1553. doi: 10.3390/ijms18071553.
In some cases, the formation of reactive species from the metabolism of xenobiotics has been linked to toxicity and therefore it is imperative to detect potential bioactivation for candidate drugs during drug discovery. Reactive species can covalently bind to trapping agents in in vitro incubations of compound with human liver microsomes (HLM) fortified with β-nicotinamide adenine dinucleotide phosphate (NADPH), resulting in a stable conjugate of trapping agent and reactive species, thereby facilitating analytical detection and providing evidence of short-lived reactive metabolites. Since reactive metabolites are typically generated by cytochrome P450 (CYP) oxidation, it is important to ensure high concentrations of trapping agents are not inhibiting the activities of CYP isoforms. Here we assessed the inhibitory properties of fourteen trapping agents against the major human CYP isoforms (CYP1A2, 2C9, 2C19, 2D6 and 3A). Based on our findings, eleven trapping agents displayed inhibition, three of which had IC values less than 1 mM (2-mercaptoethanol, -methylmaleimide and -ethylmaleimide (NEM)). Three trapping agents (dimedone, -acetyl-lysine and arsenite) did not inhibit CYP isoforms at concentrations tested. To illustrate effects of CYP inhibition by trapping agents on reactive intermediate trapping, an example drug (ticlopidine) and trapping agent (NEM) were chosen for further studies. For the same amount of ticlopidine (1 μM), increasing concentrations of the trapping agent NEM (0.007-40 mM) resulted in a bell-shaped response curve of NEM-trapped ticlopidine -oxide (TSO-NEM), due to CYP inhibition by NEM. Thus, trapping studies should be designed to include several concentrations of trapping agent to ensure optimal trapping of reactive metabolites.
在某些情况下,异生物素代谢产生的活性物质与毒性有关,因此在药物研发过程中检测候选药物的潜在生物活化作用至关重要。在化合物与人肝微粒体(HLM)加用β-烟酰胺腺嘌呤二核苷酸磷酸(NADPH)的体外孵育中,活性物质可与捕获剂共价结合,形成捕获剂与活性物质的稳定缀合物,从而便于分析检测并提供短寿命活性代谢物的证据。由于活性代谢物通常由细胞色素P450(CYP)氧化产生,因此确保高浓度的捕获剂不会抑制CYP同工酶的活性很重要。在此,我们评估了14种捕获剂对主要人类CYP同工酶(CYP1A2、2C9、2C19、2D6和3A)的抑制特性。基于我们的研究结果,11种捕获剂表现出抑制作用,其中3种的半数抑制浓度(IC)值小于1 mM(2-巯基乙醇、甲基马来酰亚胺和乙基马来酰亚胺(NEM))。3种捕获剂(达美酮、乙酰赖氨酸和亚砷酸盐)在测试浓度下未抑制CYP同工酶。为了说明捕获剂对CYP的抑制作用对活性中间体捕获的影响,选择了一种示例药物(噻氯匹定)和捕获剂(NEM)进行进一步研究。对于相同量的噻氯匹定(1 μM),由于NEM对CYP的抑制作用,捕获剂NEM浓度增加(0.007 - 40 mM)会导致NEM捕获的噻氯匹定亚砜(TSO-NEM)呈钟形响应曲线。因此,捕获研究的设计应包括几种捕获剂浓度,以确保活性代谢物的最佳捕获。